Merck’s Keytruda Fuels Projected Revenue Growth for 2025: What Lies Ahead?

Merck's Dominance in Oncology and the Role of Keytruda

Merck (MRK) has established itself as a leader in the cancer treatment market, largely due to the success of its flagship drug, Keytruda. This PD-1 inhibitor is responsible for approximately 55% of Merck’s pharmaceutical revenue and has been a major contributor to the company’s consistent financial growth in recent years.

Keytruda has received approval for a wide range of cancer types and generated nearly $31.7 billion in sales in 2025, reflecting a 7% increase from the previous year. Merck anticipates this upward trend will persist until Keytruda’s patent expires in 2028.

The drug’s expanding use in earlier-stage cancers, along with sustained demand in advanced cancer treatments, continues to fuel its sales. Merck projects further growth for Keytruda in 2026, especially following the FDA’s recent approval of both Keytruda and its subcutaneous version, Keytruda Qlex, for ovarian cancer—a new indication for the medication.

Although Keytruda’s intravenous formulation will lose exclusivity in 2028, robust sales are expected to continue up to that point. Company leadership predicts Keytruda could reach peak annual sales of $35 billion before its patent protection ends.

Strategies for Sustained Growth and Pipeline Expansion

To ensure Keytruda’s long-term success, Merck has implemented several forward-looking strategies. These include developing novel immuno-oncology combinations, such as pairing Keytruda with LAG3 and CTLA-4 inhibitors. In collaboration with Moderna, Merck is also advancing a personalized mRNA cancer vaccine (intismeran autogene, V940/mRNA-4157) in combination with Keytruda. This innovative therapy is currently in pivotal phase III trials for early-stage and adjuvant non-small cell lung cancer (NSCLC) as well as adjuvant melanoma.

Merck recently announced a restructuring of its Human Health division, creating two specialized business units: one focused on Oncology and another on Specialty, Pharma, and Infectious Diseases. This reorganization aims to sharpen commercial priorities and support sustainable growth, particularly as Merck prepares to diversify its revenue streams ahead of Keytruda’s patent expiration.

During its fourth-quarter 2025 earnings call, Merck revealed that its current pipeline could represent over $70 billion in potential commercial opportunities by the mid-2030s. This estimate is more than double the previous consensus for Keytruda’s peak sales in 2028 and marks a $20 billion increase over last year’s projection.

The company’s new business structure is designed to help Merck capitalize on this $70 billion opportunity by providing focused leadership for both oncology and specialty pharmaceuticals, enabling more effective development and launch of its growing pipeline.

Keytruda’s Rivals in the PD-L1 Inhibitor Market

Keytruda competes with several other PD-L1 inhibitors, including Bristol Myers’ Opdivo, Roche’s Tecentriq, and AstraZeneca’s Imfinzi.

• Opdivo (Bristol Myers): Approved for a variety of cancers such as lung, melanoma, and kidney, Opdivo achieved $10.05 billion in sales in 2025, an 8% year-over-year increase.
• Tecentriq (Roche): As Roche’s leading immuno-oncology therapy, Tecentriq is approved for multiple cancer types and brought in CHF 3.56 billion in 2025, up 3% from the previous year.
• Imfinzi (AstraZeneca): Imfinzi’s sales reached $6.06 billion in 2025, a 28% jump, driven by higher demand in bladder and liver cancer treatments. Its expanded indications have further strengthened AstraZeneca’s cancer portfolio.

The Next Phase of AI Investment

The artificial intelligence sector has already created significant wealth, but the most well-known companies may not offer the highest returns going forward. Emerging AI firms addressing major global challenges could present more attractive investment opportunities in the near future.

Investment Resources

Looking for expert stock picks? Download the latest recommendations from Zacks Investment Research: 7 Best Stocks for the Next 30 Days